Week Ending May 2, 2022

New data may change the standard of care for patients with advanced non-small cell lung cancer
“The phase 2 clinical trial of a multi-center study known as the COAST clinical trial has demonstrated improved outcomes using immunotherapy combinations for patients with unresectable stage III non-small cell lung cancer, according to researchers at Yale Cancer Center and participating organizations. The results are the first to demonstrate evidence of improved clinical outcomes with novel combinations of immunotherapy in this patient population. The results were published today in the Journal of Clinical Oncology.”

Driving Lung Cancer Research With Compassion
“We are writing this letter to strongly recommend Livia Szeto, B.S.N., RN, OCN, for the 2022 Extraordinary Healer® Award.”

Study Finds Risk of Overinvestigation in Patients With Lung Cancer Not Fit for Anticancer Treatment
“Among a group of patients with lung cancer who were not suitable for anticancer treatment, the researchers found that 40% underwent additional investigations after their initial CT scan before eventually receiving best supportive care.”

Early lung cancer detection improves survival rates
“The American Cancer Society estimated the numbers of new cancer cases and deaths in the United States, projecting nearly 2 million new cancer cases and more than 600,000 deaths in 2022.”

Roundtable Discussion: Riess Looks at the Options in Treating High PD-L1 NSCLC
“During a Targeted Oncology case-based roundtable event, Jonathan Wesley Riess, MD, MS, discussed the case of a 72-year-old patient with non–small cell lung cancer with high PD-L1 expression.”

What Is Rehabilitation for NSCLC?
“After you’ve finished treatment for non-small cell lung cancer (NSCLC), you may wonder what comes next. As you recover from the side effects of your cancer and its treatments, this is when what’s known as follow-up care begins.”

Mirati Therapeutics to Present New Research at the 2022 ASCO Annual Meeting Showcasing Clinical Advances of Treating KRASG12C-Mutated Lung Cancer with Investigational Adagrasib
“Mirati Therapeutics, Inc., a clinical-stage targeted oncology company today announced the presentation of new clinical research showcasing the potential of its investigational KRASG12C inhibitor, adagrasib, in a study of patients with KRASG12C-mutated non-small cell lung cancer (NSCLC) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 3 to 7, 2022 in Chicago, IL.”

Overcoming MET TKI Resistance in Patients with Non–Small Cell Lung Cancer
“In an interview with Targeted Oncology™, Yonina R. Murciano-Goroff, MD, MSc, DPhil, discussed how MET fusions impact patients with NSCLC and the issue of resistance to targeted therapies that treat MET fusion-positive disease.”

Factors in Selecting Therapy for Non-Small Cell Lung Cancer
“Expert panelists look at all factors that inform treatment selection when managing a patient diagnosed with non–small cell lung cancer.”

Biomarker Testing Practices in Non-Small Cell Lung Cancer
“Comprehensive discussion on how biomarker testing and multidisciplinary care can improve the management of non–small cell lung cancer.”

Dr Melissa Johnson Highlights Potential Lung Cancer Treatments in the Pipeline
“Melissa Johnson, MD, program director of Lung Cancer Research at Sarah Cannon, discusses the potential of certain drug classes for lung cancer.”